WE WILL BEGIN SHORTLY

 To submit text questions to today's presenters, please type your questions into the 'Q&A' box

 Today's presentation is being recorded and will be posted on the Healey & AMG Center for ALS website

https://www.massgeneral.org/neurology/als/news/webinars

HEALEY ALS Platform Trial

Weekly Q&A – Dec 10, 2020

















Healey Center

Sean M. Healey & AMG Center for ALS at Mass General






























AGENDA

- Updates on the HEALEY ALS Platform Trial
 - Study Treatments
 - Sites
 - Enrollment
- How to stay in touch and find a site near you

YOUR QUESTIONS


Perpetual Adaptive Trial Randomization Ratio 3:1; Shared Placebo Open Label Extension offered



Screening


24 weeks on study drug (active:placebo = 3:1)

How to Find a Center Near You



33 sites are actively enrolling

Contact Info of Participating Sites by State



https://www.massgeneral.org/neurology/als/research/platform-trial-sites

List of enrolling sites as of Dec 10, 2020 33 sites are enrolling

- **☑** Texas Neurology
- **™ MGH**
- **✓ UTHSCSA**
- **™** Holy Cross Hospital
- **™** Thomas Jefferson
- **Mathodist** Houston Methodist
- **™** Henry Ford Health System
- **Mathematical States** Barrow Neurological Institute
- **™** Ohio State University
- **™** Northwestern University
- **™** University of Chicago
- **Wake Forest**
- **☑** University of Nebraska Medical Center
- ✓ Loma Linda
- **™** University of Washington

- **☑** University of Iowa
- **Washington University**
- ☑ University of Pennsylvania
- **☑ University of Michigan**
- **☞** Forbes Norris MDA/ALS Research Center, CPMC
- **☑** Penn State Hershey
- ✓ UMass
- **☑** University of Miami
- **☑** University of Colorado
- **☑** Cedars-Sinai
- **✓ University of Florida**
- ☑ University of South Florida
- **☑** Columbia University
- **✓ University of Virginia**
- **☑** Emory
- **☑** University of Maryland
- SUNY Upstate

Enrollment Updates (as of Dec 10, 2020)

- 227 individuals with ALS signed informed consent
- 177 individuals were assigned to a regimen
- 153 are currently receiving study drug (active or placebo)

We will continue to update the ALS community on enrollment (website, webinars)

Patient Navigator

Catherine Small Allison Bulat

Phone: 833-425-8257 (HALT ALS)

E-mail:healeyalsplatform@mgh.harvard.edu

For More Updates

Weekly webinars

The idea of came from our Patient Advisory Committee: we are excited to be talking with you on a weekly basis and take any questions you might have

Find the schedule and registration links on our website

https://www.massgeneral.org/neurology/als/research/platform-trial-news/

Coming up: webinars about each drug's mechanism of action and science